Skip to main content
SpringerLink
Log in

Treat bipolar depression with atypical antipsychotics and mood stabilisers; new therapies require further study

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Patients with bipolar disorder frequently suffer from episodes of depression, which is a major cause of morbidity. A range of atypical antipsychotics and mood stabilisers are recommended in guidelines for the treatment of bipolar depression but there is no consensus on which therapies should be used in the first line. Many patients remain symptomatic and experience relapse despite treatment. Pharmacotherapies with efficacy in other depressive disorders and those with novel mechanisms of action (including those targeting neuronal plasticity, inflammation, mitochondrial function) are currently being investigated for efficacy in bipolar depression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McIntyre RS, Calabrese JR. Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Curr Med Res Opin. 2019;35(11):1993–2005.

    Article  PubMed  Google Scholar 

  2. McIntyre RS, Berk M, Brietzke E, et al. Bipolar disorders. Lancet. 2020;396(10265):1841–56.

    Article  CAS  PubMed  Google Scholar 

  3. Tondo L, Vázquez GH, Baldessarini RJ. Options for pharmacological treatment of refractory bipolar depression. Curr Psychiatry Rep. 2014;16:431.

    Article  PubMed  Google Scholar 

  4. Keramatian K, Chakrabarty T, DuBois A, et al. New pharmacologic approaches to the treatment of bipolar depression. Drugs. 2023;83(10):843–63.

    Article  PubMed  Google Scholar 

  5. Malhi GS, Bell E, Boyce P, et al. The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary. Bipolar Disord. 2020;22(8):805–21.

    Article  PubMed  Google Scholar 

  6. National Institute for Health and Care Excellence. Bipolar disorder: the assessment and management of bipolar disorder (2023 updated edition). 2014. https://www.nice.org.uk/. Accessed 22 Dec 2023.

  7. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97–170.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Bschor T, Baethge C, Grunze H, et al. S3-Leitlinie Bipolare Störungen – 1. Update 2019 Was ist neu in der Pharmakotherapie? [German S3 guidelines on bipolar disorders-first update 2019: what is new in pharmacotherapy?]. Nervenarzt. 2020;91(3):216–21.

    Article  CAS  PubMed  Google Scholar 

  9. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711–22.

    Article  CAS  PubMed  Google Scholar 

  10. Yalin N, Young AH. Pharmacological treatment of bipolar depression: what are the current and emerging options? Neuropsychiatr Dis Treat. 2020;16:1459–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bahji A, Ermacora D, Stephenson C, et al. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis. J Affect Disord. 2020;269:154–84.

    Article  CAS  PubMed  Google Scholar 

  12. Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. 2021;178:1098–106.

    Article  PubMed  Google Scholar 

  13. Suppes T, Durgam S, Kozauer SG, et al. Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: results from a randomized placebo-controlled clinical trial. Bipolar Disord. 2023;25(6):478–88.

    Article  CAS  PubMed  Google Scholar 

  14. Yatham LN, Vieta E, Earley W. Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial. Int Clin Psychopharmacol. 2020;35:147–56.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kang SG, Cho SE, Na KS, et al. Clinical usefulness of amisulpride add-on therapy in schizophrenia patients without treatment response to second-generation antipsychotics. Clin Psychopharmacol Neurosci. 2021;19(1):117–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Zangani C, Giordano B, Stein HC, et al. Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: a systematic review and meta-analysis. Hum Psychopharmacol. 2021;36(6): e2801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–42.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Chen MH, Cheng CM, Gueorguieva R, et al. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study. Neuropsychopharmacology. 2019;44(12):2112–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Walkery A, Leader LD, Cooke E, et al. Review of allopregnanolone agonist therapy for the treatment of depressive disorders. Drug Des Devel Ther. 2021;15:3017–26.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Sartim AG, Guimarães FS, Joca SRL. Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-possible involvement of 5-HT1A and CB1 receptors. Behav Brain Res. 2016;303:218–27.

    Article  CAS  PubMed  Google Scholar 

  21. Loebel A, Koblan KS, Tsai J, et al. A randomized, double-blind, placebo-controlled proof-of-concept trial to evaluate the efficacy and safety of non-racemic amisulpride (SEP-4199) for the treatment of bipolar I depression. J Affect Disord. 2022;296:549–58.

    Article  CAS  PubMed  Google Scholar 

  22. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793–802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Zarate CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Grunebaum MF, Ellis SP, Keilp JG, et al. Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial. Bipolar Disord. 2017;19:176–83.

    Article  CAS  PubMed  Google Scholar 

  25. Gunduz-Bruce H, Lasser R, Nandy I, et al. Open-label, phase 2 trial of the oral neuroactive steroid GABAA receptor positive allosteric modulator zuranolone in bipolar disorder I and II [abstract no. 182]. In: Psych Congerss Virtual Experience. 2020.

  26. Bauer IE, Green C, Colpo GD, et al. A double-blind, randomized, placebo-controlled study of aspirin and N-acetylcysteine as adjunctive treatments for bipolar depression. J Clin Psychiatry. 2018;80(1):18m12200.

    Article  PubMed  Google Scholar 

  27. Berk M, Turner A, Malhi GS, et al. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Med. 2019;17(1):18.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ellegaard PK, Licht RW, Nielsen RE, et al. The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: a randomized placebo-controlled study. J Affect Disord. 2019;245:1043–51.

    Article  CAS  PubMed  Google Scholar 

  29. Magalhães PV, Dean OM, Bush AI, et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Braz J Psychiatry. 2011;33(4):374–8.

    Article  PubMed  Google Scholar 

  30. Husain MI, Chaudhry IB, Khoso AB, et al. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. Lancet Psychiatry. 2020;7:515–27.

    Article  PubMed  Google Scholar 

  31. McIntyre RS, Subramaniapillai M, Lee Y, et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial. JAMA Psychiat. 2019;76:783–90.

    Article  Google Scholar 

  32. Pinto JV, Crippa JAS, Cereser KM, et al. Cannabidiol as an adjunctive treatment for acute bipolar depression: a pilot study. Can J Psychiatry. 2024;69(4):242–51. https://doi.org/10.1177/07067437231209650.

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Simon Fung

Authors
  1. Simon Fung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simon Fung.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

Adis author S. Fung is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fung, S. Treat bipolar depression with atypical antipsychotics and mood stabilisers; new therapies require further study. Drugs Ther Perspect 40, 109–114 (2024). https://doi.org/10.1007/s40267-024-01054-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-024-01054-z

Search

Navigation